JP2018530623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530623A5 JP2018530623A5 JP2018539238A JP2018539238A JP2018530623A5 JP 2018530623 A5 JP2018530623 A5 JP 2018530623A5 JP 2018539238 A JP2018539238 A JP 2018539238A JP 2018539238 A JP2018539238 A JP 2018539238A JP 2018530623 A5 JP2018530623 A5 JP 2018530623A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- ammonium salt
- composition according
- mitomycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 17
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 8
- 150000003863 ammonium salts Chemical class 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229960004857 mitomycin Drugs 0.000 claims 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 2
- 229940122361 Bisphosphonate Drugs 0.000 claims 2
- 229940062527 alendronate Drugs 0.000 claims 2
- 150000004663 bisphosphonates Chemical class 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 239000000232 Lipid Bilayer Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000633 dextran sulfate Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229930182480 glucuronide Natural products 0.000 claims 1
- 150000008134 glucuronides Chemical class 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229940015872 ibandronate Drugs 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims 1
- 229950010733 neridronic acid Drugs 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229940046231 pamidronate Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229940089617 risedronate Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims 1
- 229960004291 sucralfate Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242097P | 2015-10-15 | 2015-10-15 | |
| US62/242,097 | 2015-10-15 | ||
| PCT/US2016/057176 WO2017066667A1 (en) | 2015-10-15 | 2016-10-14 | Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530623A JP2018530623A (ja) | 2018-10-18 |
| JP2018530623A5 true JP2018530623A5 (enExample) | 2019-11-14 |
Family
ID=57209906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539238A Pending JP2018530623A (ja) | 2015-10-15 | 2016-10-14 | ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10617672B2 (enExample) |
| EP (1) | EP3362099A1 (enExample) |
| JP (1) | JP2018530623A (enExample) |
| AU (1) | AU2016337370A1 (enExample) |
| CA (1) | CA3001699A1 (enExample) |
| WO (1) | WO2017066667A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017066667A1 (en) | 2015-10-15 | 2017-04-20 | Lipomedix Pharmaceuticals Ltd. | Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c |
| WO2020058372A1 (en) * | 2018-09-19 | 2020-03-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
| CN109260155B (zh) * | 2018-11-05 | 2021-04-06 | 杭州高田生物医药有限公司 | 伊立替康脂质体制剂及其制备与应用 |
| US12171746B2 (en) | 2019-01-11 | 2024-12-24 | Lipomedix Pharmaceuticals Ltd. | Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture |
| WO2021225113A1 (ja) * | 2020-05-08 | 2021-11-11 | 国立大学法人京都工芸繊維大学 | イオン性化学種濃縮方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US7303760B2 (en) * | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
| US20050129753A1 (en) * | 2003-11-14 | 2005-06-16 | Gabizon Alberto A. | Method for drug loading in liposomes |
| EP2531175A2 (en) | 2010-02-01 | 2012-12-12 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Liposomes comprising amphipathic drugs and method for their preparation |
| EP2731591B1 (en) * | 2011-07-13 | 2020-06-17 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Liposomes co-encapsulating a bisphosphonate and an amphipathic agent |
| JP2014523444A (ja) * | 2011-07-19 | 2014-09-11 | エスティーシー． ユーエヌエム | 癌の炎症性環境に基づいて治療用積載物を放出する、腹腔内投与されるナノ担体 |
| US9849087B2 (en) * | 2011-11-08 | 2017-12-26 | The Board Of Trustees Of The University Of Arkansas | Methods and compositions for X-ray induced release from pH sensitive liposomes |
| CN103622912B (zh) * | 2013-12-05 | 2016-02-24 | 常州金远药业制造有限公司 | 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法 |
| WO2015191576A1 (en) * | 2014-06-09 | 2015-12-17 | Lipomedix Pharmaceuticals Ltd. | Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy |
| WO2017066667A1 (en) | 2015-10-15 | 2017-04-20 | Lipomedix Pharmaceuticals Ltd. | Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c |
-
2016
- 2016-10-14 WO PCT/US2016/057176 patent/WO2017066667A1/en not_active Ceased
- 2016-10-14 AU AU2016337370A patent/AU2016337370A1/en not_active Abandoned
- 2016-10-14 EP EP16788348.7A patent/EP3362099A1/en not_active Withdrawn
- 2016-10-14 JP JP2018539238A patent/JP2018530623A/ja active Pending
- 2016-10-14 US US15/768,526 patent/US10617672B2/en active Active
- 2016-10-14 CA CA3001699A patent/CA3001699A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250152511A1 (en) | Platinum complexes and uses thereof | |
| JP7676056B2 (ja) | γポリグルタミン酸化テトラヒドロ葉酸およびその使用 | |
| Mi et al. | Clinical translation of Self‐Assembled cancer nanomedicines | |
| Katsumi et al. | Bone-targeted drug delivery systems and strategies for treatment of bone metastasis | |
| US20210077397A1 (en) | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents | |
| JP7028774B2 (ja) | ギンセノシドを膜材料として有するリポソームならびにその調製および使用 | |
| Meng et al. | Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice | |
| JP2014520849A5 (enExample) | ||
| JP2019523757A5 (enExample) | ||
| JP2016006096A5 (enExample) | ||
| JP2015519346A5 (enExample) | ||
| WO2007115033A3 (en) | Layered nanoparticles for sustained release of small molecules | |
| De Rosa et al. | Bisphosphonates and cancer: what opportunities from nanotechnology? | |
| CN105705152A (zh) | 基于脂质的铂化合物和纳米粒子 | |
| Lin et al. | Epigenetic inhibition assisted chemotherapeutic treatment of lung cancer based on artificial exosomes | |
| RU2019115688A (ru) | Липосомальный препарат для применения для лечения злокачественного новообразования | |
| Motamarry et al. | Thermosensitive liposomes | |
| Peng et al. | Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2′-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles | |
| JP2019507764A5 (enExample) | ||
| CN112437674A (zh) | 用于药物递送的脂质前药 | |
| JP2018530623A (ja) | ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物 | |
| JP2019536783A5 (enExample) | ||
| Adema et al. | Innovations and opportunities to improve conventional (deoxy) nucleoside and fluoropyrimidine analogs in cancer | |
| SG194759A1 (en) | Novel precursors of glutamate derivatives | |
| Swain et al. | Systematic review on recent advancements and liposomal technologies to develop stable liposome |